Genmab

CompanyDenmarkFounded 1998

Genmab develops 3 assets, the furthest in phase 3 (epcoritamab in diffuse large B-cell lymphoma). Mostly antibody acting on apoptosis, CD3E and MS4A1; based in Denmark, founded in 1998.

3
Assets
Furthest: Phase 3; 9
Trials: 4
Signals

Pipeline

epcoritamab
Bispecific antibody targeting CD3 and CD20 to induce T-cell mediated lymphoma cell killing
Phase 3, Antibody, Apoptosis, CD3E, diffuse large B-cell lymphoma
Epkinly
Bispecific CD20-directed CD3 T-cell engager antibody
Phase 3, Antibody, Apoptosis, CD3E, diffuse large B-cell lymphoma, DLBCL
rinatabart sesutecan
Folate receptor alpha (FOLR1)-directed antibody-drug conjugate.
Phase 2, Antibody, DNA damage response, Apoptosis, platinum-resistant ovarian cancer

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

Evidence behind the mechanisms3
Trials12
Signals4
Integrity notices1
Similar companies6

Updated 8 Oct 2026 · 24 sources